ASC24
2.4.2024 10:38:26 CEST | Business Wire | Press release
The 2024 ASC Student Supercomputer Challenge (ASC24) finals are scheduled to take place at Shanghai University from April 9 to 13, 2024. Among the over 300 teams representing universities worldwide, only 25 have progressed to the finals. Throughout the competition finals, teams will face a series of challenges including optimizing large language model (LLM) inference, tackling tasks like OpenCAEPoro and GoMars, as well as competing in high-performance benchmarks such as HPL and HPCG. Additionally, teams will engage in group competitions and tackle a mystery application. Each team will present their projects before the jury, contending for prestigious awards including the Champion, Silver Prize, e Prize, and the Highest LINPACK.
The ASC24 Student Supercomputer Challenge Finals
Date |
Time |
Agenda |
April 9 |
08:00-20:00 |
Rule Announcement, Cluster Setup/Testing |
April 10 |
08:00-20:00 |
Cluster Setup/Testing |
April 11 |
08:00-18:00 |
Competition: HPL & HPCG, Group Competition, LLM |
April 12 |
08:00-18:00 |
Competition: OpenCAEPoro, GoMars, mystery APP |
14:00-17:00 |
The 33rd HPC Connection Workshop |
|
April 13 |
08:00-12:10 |
Finalist Teams Presentations before the Jury |
15:00-17:30 |
Closing and awards ceremony |
ASC is committed to assisting students in addressing state-of-the-art scientific challenges through the utilization of the most advanced computing products and technologies. This endeavor aims to explore emerging research paradigms and confront the various challenges humanity faces. The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.
The prestigious e Prize will be bestowed upon the winners of the OpenCAEPoro task, which entails simulating the seepage of multiphase fluids, such as oil, gas, and water, particularly within contexts relevant to petroleum extraction. Competitors are tasked with skillfully optimizing large-scale parallel computing processes, emphasizing enhancements in computing performance and parallel efficiency of discrete algorithms.
In the GoMars task, participating teams are challenged with optimizing parallel communication and refining computational load balancing within the dynamic framework of GoMars. GoMars represents a new generation of Mars atmosphere models. The objective is to enhance operational efficiency and achieve more precise predictions of the Martian atmosphere.
In the LLM Inference Optimization Challenge, participating teams are assigned the task of constructing and refining inference engines utilizing the widely employed open-source LLM, AquilaChat2-34B. The primary objective is to expedite inference processes by employing 4-bit or less quantization while maintaining overall accuracy.
Alongside the primary challenges, the finals will include a Group Competition aimed at fostering cross-team collaboration among students. Students will be randomly allocated to one of five groups. Each group will work collectively on the ParaSeis task, employing ParaSeis to simulate seismic wave propagation and refine the algorithm through collaborative communication. The group's performance will be evaluated based on the average score of its constituent teams, with the group achieving the highest score declared as the victor.
The finals will bring together formidable teams from renowned universities, including Peking University - the champion of the 10th ASC onsite finals, the Chinese University of Hong Kong - the champion of the 10th ASC virtual finals, University of Science and Technology of China, Huazhong University of Science and Technology, Shanghai Jiao Tong University, and Friedrich-Alexander-University Erlangen-Nuremberg.
Numerous new teams are set to join the finals, with Shanghai University, Lanzhou University, and Southern University of Science and Technology among them. Excitement surrounds the debut of teams from the National University of Cordoba, Macau University of Science and Technology, and Southwest Petroleum University, making their inaugural ASC finals appearance this year. The enthusiasm of these new contenders promises to elevate the competition, ensuring an intense battle until the very end.
About ASC
The ASC Student Supercomputer Challenge is the world's largest student supercomputer competition, sponsored and organized by the Asia Supercomputer Community with support from experts and institutions across Asia, Europe, and America. The main objectives of ASC are to encourage the exchange and training of young supercomputing talent from different countries, improve supercomputing applications and R&D capacity, boost the development of supercomputing, and promote technical and industrial innovation. The first ASC Student Supercomputer Challenge was held in 2012 and has since attracted over 10,000 undergraduates from all over the world. Learn more for ASC at http://www.asc-events.net/StudentChallenge/index.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402763009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
